Literature DB >> 22119468

(±)-2-(N-tert-Butylamino)-3'-[(125)I]-iodo-4'-azidopropiophenone: a dopamine transporter and nicotinic acetylcholine receptor photoaffinity ligand based on bupropion (Wellbutrin, Zyban).

David J Lapinsky1, Shaili Aggarwal, Tammy L Nolan, Christopher K Surratt, John R Lever, Rejwi Acharya, Roxanne A Vaughan, Akash Pandhare, Michael P Blanton.   

Abstract

Towards addressing the knowledge gap of how bupropion interacts with the dopamine transporter (DAT) and nicotinic acetylcholine receptors (nAChRs), a ligand was synthesized in which the chlorine of bupropion was isosterically replaced with an iodine and a photoreactive azide was added to the 4'-position of the aromatic ring. Analog (±)-3 (SADU-3-72) demonstrated modest DAT and α4β2 nAChR affinity. A radioiodinated version was shown to bind covalently to hDAT expressed in cultured cells and affinity-purified, lipid-reincorporated human α4β2 neuronal nAChRs. Co-incubation of (±)-[(125)I]-3 with non-radioactive (±)-bupropion or (-)-cocaine blocked labeling of these proteins. Compound (±)-[(125)I]-3 represents the first successful example of a DAT and nAChR photoaffinity ligand based on the bupropion scaffold. Such ligands are expected to assist in mapping bupropion-binding pockets within plasma membrane monoamine transporters and ligand-gated nAChR ion channels.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22119468      PMCID: PMC3249008          DOI: 10.1016/j.bmcl.2011.10.086

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  22 in total

1.  Dopamine transporter ligand binding domains. Structural and functional properties revealed by limited proteolysis.

Authors:  R A Vaughan; M J Kuhar
Journal:  J Biol Chem       Date:  1996-08-30       Impact factor: 5.157

2.  Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.

Authors:  David J Lapinsky; Ranganadh Velagaleti; Nageswari Yarravarapu; Yi Liu; Yurong Huang; Christopher K Surratt; John R Lever; James D Foster; Rejwi Acharya; Roxanne A Vaughan; Howard M Deutsch
Journal:  Bioorg Med Chem       Date:  2010-11-04       Impact factor: 3.641

3.  15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.

Authors:  Maurizio Fava; A John Rush; Michael E Thase; Anita Clayton; Stephen M Stahl; James F Pradko; J Andrew Johnston
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

4.  Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue.

Authors:  Okechukwu T Ukairo; Corry D Bondi; Amy Hauck Newman; Santosh S Kulkarni; Alan P Kozikowski; Stephen Pan; Christopher K Surratt
Journal:  J Pharmacol Exp Ther       Date:  2005-05-05       Impact factor: 4.030

5.  Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties.

Authors:  Kyle C Schmitt; Juan Zhen; Prashant Kharkar; Manoj Mishra; Nianhang Chen; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurochem       Date:  2008-09-11       Impact factor: 5.372

6.  1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.

Authors:  Peter C Meltzer; David Butler; Jeffrey R Deschamps; Bertha K Madras
Journal:  J Med Chem       Date:  2006-02-23       Impact factor: 7.446

7.  Synthesis of five-, six-, and seven-membered ring lactams by CpRh complex-catalyzed oxidative N-heterocyclization of amino alcohols.

Authors:  Ken-ichi Fujita; Yoshinori Takahashi; Maki Owaki; Kazunari Yamamoto; Ryohei Yamaguchi
Journal:  Org Lett       Date:  2004-08-05       Impact factor: 6.005

8.  Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.

Authors:  F Ivy Carroll; Bruce E Blough; Philip Abraham; Andrew C Mills; J Ashley Holleman; Scott A Wolckenhauer; Ann M Decker; Antonio Landavazo; K Timothy McElroy; Hernán A Navarro; Michael B Gatch; Michael J Forster
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

9.  Differential binding of tropane-based photoaffinity ligands on the dopamine transporter.

Authors:  R A Vaughan; G E Agoston; J R Lever; A H Newman
Journal:  J Neurosci       Date:  1999-01-15       Impact factor: 6.167

Review 10.  The use of bupropion SR in cigarette smoking cessation.

Authors:  Scott Wilkes
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more
  4 in total

1.  Bupropion binds to two sites in the Torpedo nicotinic acetylcholine receptor transmembrane domain: a photoaffinity labeling study with the bupropion analogue [(125)I]-SADU-3-72.

Authors:  Akash Pandhare; Ayman K Hamouda; Brandon Staggs; Shaili Aggarwal; Phaneendra K Duddempudi; John R Lever; David J Lapinsky; Michaela Jansen; Jonathan B Cohen; Michael P Blanton
Journal:  Biochemistry       Date:  2012-03-15       Impact factor: 3.162

2.  Dextroamphetamine and Pramipexole Combination for Treatment-Resistant Unipolar Depression.

Authors:  Maju Mathew Koola; Jan Fawcett
Journal:  Psychiatr Ann       Date:  2016-08-12

3.  Evolution of a Compact Photoprobe for the Dopamine Transporter Based on (±)-threo-Methylphenidate.

Authors:  David J Lapinsky; Nageswari Yarravarapu; Tammy L Nolan; Christopher K Surratt; John R Lever; Michael Tomlinson; Roxanne A Vaughan; Howard M Deutsch
Journal:  ACS Med Chem Lett       Date:  2012-03-11       Impact factor: 4.345

4.  Novel Azido-Iodo Photoaffinity Ligands for the Human Serotonin Transporter Based on the Selective Serotonin Reuptake Inhibitor (S)-Citalopram.

Authors:  Vivek Kumar; Nageswari Yarravarapu; David J Lapinsky; Danielle Perley; Bruce Felts; Michael J Tomlinson; Roxanne A Vaughan; L Keith Henry; John R Lever; Amy Hauck Newman
Journal:  J Med Chem       Date:  2015-07-08       Impact factor: 7.446

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.